Not too surprising given the amount of information primary care doctors need to have. I was more surprised at the lower than expected results for oncologists – but again, care after one is in remission is more in the hands of the primary care doctors, as in the case of many chronic diseases.
The main long-term effects studied:
- Heart problems from Adriamycin
- Peripheral neuropathy (nerve damage to the arms and legs) from Taxol and Eloxatin (I have some of this in my feet from not sure which mix of ‘cocktails’)
- Early menopause and second cancers from Cytoxin (cyclophosphamide), which I have had a lot of over the past few years
One of the better tools I have seen is a follow-up chart for stem cell transplant patients to give to their primary care doctor. The other, of course, is to ensure that each of us discusses the long-term effects of any treatment with one’s oncologist or haematologist, recognizing of course that with many treatments, there is a trade-off between keeping us alive now and risks further down the road. To use Keynes in another context, in the long-run, we are all dead, most treatment is to push to long-run further back in time.